TY - JOUR
T1 - Metabolic adaptation of acute lymphoblastic leukemia to the central nervous system microenvironment depends on stearoyl-CoA desaturase
AU - Savino, Angela Maria
AU - Fernandes, Sara Isabel
AU - Olivares, Orianne
AU - Zemlyansky, Anna
AU - Cousins, Antony
AU - Markert, Elke K.
AU - Barel, Shani
AU - Geron, Ifat
AU - Frishman, Liron
AU - Birger, Yehudit
AU - Eckert, Cornelia
AU - Tumanov, Sergey
AU - MacKay, Gillian
AU - Kamphorst, Jurre J.
AU - Herzyk, Pawel
AU - Fernández-García, Jonatan
AU - Abramovich, Ifat
AU - Mor, Inbal
AU - Bardini, Michela
AU - Barin, Ersilia
AU - Janaki-Raman, Sudha
AU - Cross, Justin R.
AU - Kharas, Michael G.
AU - Gottlieb, Eyal
AU - Izraeli, Shai
AU - Halsey, Christina
N1 - Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Springer Nature America, Inc.
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Metabolic reprogramming is a key hallmark of cancer, but less is known about metabolic plasticity of the same tumor at different sites. Here, we investigated the metabolic adaptation of leukemia in two different microenvironments, the bone marrow and the central nervous system (CNS). We identified a metabolic signature of fatty acid synthesis in CNS leukemia, highlighting stearoyl-CoA desaturase (SCD) as a key player. In vivo SCD overexpression increases CNS disease, whereas genetic or pharmacological inhibition of SCD decreases CNS load. Overall, we demonstrated that leukemic cells dynamically rewire metabolic pathways to suit local conditions and that targeting these adaptations can be exploited therapeutically.
AB - Metabolic reprogramming is a key hallmark of cancer, but less is known about metabolic plasticity of the same tumor at different sites. Here, we investigated the metabolic adaptation of leukemia in two different microenvironments, the bone marrow and the central nervous system (CNS). We identified a metabolic signature of fatty acid synthesis in CNS leukemia, highlighting stearoyl-CoA desaturase (SCD) as a key player. In vivo SCD overexpression increases CNS disease, whereas genetic or pharmacological inhibition of SCD decreases CNS load. Overall, we demonstrated that leukemic cells dynamically rewire metabolic pathways to suit local conditions and that targeting these adaptations can be exploited therapeutically.
UR - http://www.scopus.com/inward/record.url?scp=85099024527&partnerID=8YFLogxK
U2 - 10.1038/s43018-020-00115-2
DO - 10.1038/s43018-020-00115-2
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 33479702
AN - SCOPUS:85099024527
SN - 2662-1347
VL - 1
SP - 998
EP - 1009
JO - Nature Cancer
JF - Nature Cancer
IS - 10
ER -